Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks

• Natera (NTRA) grew gross 34.66% year-over-year successful Q3 2025 and has rallied astir 70% since Q3 2025. Druckenmiller holds $517.4M successful Natera.

• Insmed (INSM) gross surged 52.36% year-over-year successful Q3 2025. The banal climbed from $25 to $189 since Q2 2024.

• Teva (TEVA) has rallied implicit 300% since June 2023. Druckenmiller accumulated shares each 4th from Q3 2024 to Q3 2025.

• If you’re reasoning astir retiring oregon cognize idiosyncratic who is, determination are 3 speedy questions causing galore Americans to recognize they tin discontinue earlier than expected. instrumentality 5 minutes to larn much here

Stanley Druckenmiller is simply a Wall Street fable whose trades are genuinely worthy tracking owed to however consistently helium has been winning. He has been piling into Natera (NASDAQ:NTRA), Insmed (NASDAQ:INSM), and Teva Pharmaceuticals (NYSE:TEVA) arsenic of late, and we'll get into why.

Druckenmiller archetypal gained fame by managing George Soros's Quantum Fund, wherever helium orchestrated the $10 cardinal currency stake that "broke the Bank of England" successful 1992. Since founding Duquesne Capital Management successful 1981, he's delivered annualized returns exceeding 30% earlier closing to extracurricular investors successful 2010.

He present manages a household bureau that has continued beating the marketplace with stellar numbers. If you privation to bushed the market, researching Druckenmiller's buys and possibly copying them tin beryllium a large mode to bushed the market, arsenic that has historically paid off.

Druckenmiller's biggest holding is Natera. It is simply a objective familial investigating institution that specializes successful non-invasive, cell-free DNA (cfDNA) investigating technology. NTRA banal has been 1 of Druckenmiller's biggest winning moves arsenic it has gained implicit 500% since bottoming retired successful October 2023.

Druckenmiller built up his involvement arsenic the banal traded sideways passim precocious 2022 to aboriginal 2023. As NTRA banal yet broke retired and started rallying, Druckenmiller kept adding to his stake.

He lone took profits successful Q1 2025 and again successful Q2 2025 earlier buying the dip successful Q3 2025.

The banal has gained astir 70% since that dip and is continuing to rally higher.

Growth has been precise strong. Revenue grew 34.66% year-over-year successful Q3 2025 and bushed expert estimates. Natera is inactive loss-making, but analysts expect losses to narrow. EPS is expected to crook affirmative successful 2028 with gross continuing to turn by treble digits done the adjacent decade.

NTRA banal constitutes 12.74% of Druckenmiller's portfolio. His holdings present are worthy $517.4 million.

Insmed is simply a biopharma institution that mostly focuses connected pulmonary conditions. The flagship merchandise is ARIKAYCE, which is the archetypal and lone FDA-approved therapy for refractory Mycobacterium avium analyzable (MAC).